Acadia Pharmaceuticals | ACAD - Debt



Acadia Pharmaceuticals reported $56.29M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
ALKERMES USD 72.68M 72.68M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Corcept Therapeutics USD 6.6M 6.6M Jun/2025
Cytokinetics USD 658.13M 1.01M Mar/2025
Eisai JPY 187.52B 31.58B Mar/2025
Eli Lilly USD 39.9B 1.39B Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
J&J USD 52.25B 15.62B Mar/2025
Moderna USD 741M 4M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Pfizer USD 60.93B 1.18B Jun/2025
Prothena USD 9.78M 9.78M Jun/2025
PTC Therapeutics USD 286.01M 2.12B Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025